Inside the Boardroom Siege: Why Wendy’s Rejected Trian’s $1.4B Takeout and Triggered a Poison Pill Defense

Executive Takeaways

• Defensive Maneuver: Wendy’s board unanimously rejected a $1.4 billion ($28.50 per share) acquisition proposal from Nelson Peltz’s Trian Fund Management, countering with a rigorous "poison pill" shareholder rights plan.
• Valuation Friction: The core dispute centers on capital allocation, EBITDA multiples, and enterprise ROI, with the board maintaining that Trian’s bid severely undervalues the quick-service restaurant (QSR) giant's long-term infrastructure scalability and digital transformation.
• Control Struggle: Trian, already holding nearly 19% of Wendy's stock, faces a high-stakes proxy contest or revised hostile tender offer as market liquidity and institutional risk mitigation strategies shift across the broader consumer discretionary
  Related Newsroom Intelligence & Analysis

  Meta's Desktop Maneuver: Inside Instagram’s Strategic Playbook to Decapitate CapCut →